Skip to content

General Discussion

A place to talk about whatever you want

7 Topics 20 Posts
The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB), including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
  • Pre-NOC storyboard review

    2
    0 Votes
    2 Posts
    255 Views
    Jennifer CarrollJ
    Hello @Jennifer-Thomson It sounds like this would fall under a PILOT: Administrative Guideline for the Review of Pre-NOC Advertising Submissions. We’d get the file to “no further comments” pending review of the layout (video) post NOC. Please reach out to admin to discuss the specifics so that we can ensure we’re understanding the request and facilitating the best possible pathway to approval.
  • Citing patient preference in a patient profile

    3
    0 Votes
    3 Posts
    225 Views
    A
    Hi @Jennifer-Carroll Thank you!
  • Product is "in stock" claim

    4
    0 Votes
    4 Posts
    322 Views
    Jennifer CarrollJ
    Hi @support A strictly informational statement about stock such as “Product X 5mg dose now back in stock” could be considered exempt. The inclusion of the indication statement renders it no longer exempt. The inclusion of a product photo MAY render it no longer exempt. This piece should likely be submitted for an exempt opinion to assess if the product photo can be used while meeting exempt criteria.
  • PAAB Code - Post hoc analysis

    2
    0 Votes
    2 Posts
    279 Views
    Jennifer CarrollJ
    Hello @msargeant Apologies for not seeing this question sooner. Per 3.1.1, post-hoc analysis are generally not considered acceptable evidence at this time. The circumstance in which post-hoc analyses would be considered acceptable is outlined in the statement that follows that copy which states “Data included in the TMA may be acceptable”. HTH.
  • Clarification on Product Available now! message in the APS

    3
    0 Votes
    3 Posts
    588 Views
    S
    Thank you @Jennifer-Carroll!
  • Clarification on indication inclusion in multi-Product APS

    5
    0 Votes
    5 Posts
    890 Views
    S
    Thank you @Jennifer-Carroll. This is very helpful!
  • Welcome to your NodeBB!

    1
    0 Votes
    1 Posts
    263 Views
    No one has replied
  • Healthcare Professional Tour

    1
    0 Votes
    1 Posts
    17k Views
    No one has replied
  • Industry Tour

    1
    0 Votes
    1 Posts
    7k Views
    No one has replied
  • Patient Tour

    1
    0 Votes
    1 Posts
    2k Views
    No one has replied
  • This topic is deleted!

    1
    0 Votes
    1 Posts
    100 Views
    No one has replied